Direxion mRNA ETF
Data updated: 2023-06-29
C000232435 — Direxion mRNA ETF. Europe Blend / Core Equity · $126.22K AUM · 0.65% expense ratio. Holdings, fees, performance and SEC filings.
C000232435 Fund Overview
Direxion mRNA ETF is a US ETF managed by Direxion Shares ETF Trust, categorised as Europe Blend / Core Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Direxion Shares ETF Trust
- Category: Europe Blend / Core Equity
- Assets under management: $126.22K
- 1-year return: -1.0%
- SEC CIK: 0001424958
- SEC series ID: S000074486
- Share class ID: C000232435
C000232435 Investment Objective and Strategy
Direxion mRNA ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Direxion Shares ETF Trust.
Investment objective
The Direxion mRNA ETF (the Fund) seeks investment results, before fees and expenses, that track the BITA Messenger RNA Technology Index (the Index).
Principal investment strategy
The Fund, under normal circumstances, invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities that comprise the Index or investments with economic characteristics similar to the securities included in the Index . The Index provides exposure to the performance of companies, publicly listed in the United States, Canada and Europe, that are leading the development and application of messenger RNA (mRNA) technology. mRNA is a single-stranded ribonucleic acid (RNA) molecule that is complementary to one of the DNA strands of a gene. mRNA plays a vital role in protein synthesis in the human body, and mRNA technologies leverage this vital role to enable targeted cells to produce proteins that enable the body to fight or prevent a given disease. As an example, mRNA technology is the basis for certain COVID-19 vaccines.
To be eligible for inclusion in the Index, a company must satisfy at least one of the following conditions: Be involved in the commercialization of products and therapies based on mRNA technologies or sister RNA technologies (i.e., small interfering RNA, micro RNA); Be classified as a clinical stage biotechnology company with focus in the development of products and therapies that leverage mRNA technology; Have a portfolio of active, approved mRNA technology-focused clinical trials; or Have any granted, active patents with demonstrated involvement of mRNA technology. The list above establishes the universe of securities from which the Index constituents are selected. To be selected for inclusion in the Index, a company must have a minimum thematic exposure of 50%. To calculate the thematic exposure score, the following criteria are applied (if a company satisfies more than one criteria, the largest exposure score applies): Companies deriving at least 50% of their revenue from the commercialization of products and therapies based on mRNA technology, or sister RNA technologies, are attributed a thematic exposure score of 100%.
Companies with a declared (based on company headline communications, such as press releases) focus on the development and commercialization of mRNA technology-based products and therapies are attributed a thematic exposure score of 80%. Companies with a portfolio of active, approved mRNA technology-focused clinical trials, representing at least 50% of the total number of active clinical trials launched by the company, are attributed a thematic exposure score of 80%. Clinical-stage companies with at least one active, approved mRNA technology-focused clinical trial are attributed a thematic exposure score of 50%. Additionally, eligible companies must meet certain market capitalization and liquidity requirements. Index constituents are weighted based on a modified free float market capitalization and reconstituted and rebalanced quarterly.
As of December 30, 2022, the Index was comprised of 20 constituents, which had a median total market capitalization of $2.2 billion, total market capitalizations ranging from $ 287.6 million to $74.1 billion, and was concentrated in the healthcare sector. The components of the Index and the percentages represented by various sectors in the Index may change over time. The Fund will concentrate its investment in a particular industry or group of industries ( i.e. , hold 25% or more of its total assets in the stocks of a particular industry or group of industries) to approximately the same extent as the Index is so concentrated. The Fund uses a passive or indexing approach to attempt to achieve its investment objective. Although the Fund intends to fully replicate the Index, at times the Fund may hold a representative sample of the securities in the Index that have aggregate characteristics similar to those of the Index.
This means the Fund may not hold all of the securities included in the Index, its weighting of investment exposure to such securities or industries may be different from that of the Index and it may hold securities that are not included in the Index. The Fund will rebalance its portfolio when the Index rebalances. The Fund may lend securities representing up to one-third of the value of the Funds total assets (including the value of the collateral received). The Fund is non-diversified, meaning that a relatively high percentage of its assets may be invested in a limited number of issuers of securities. Additionally, the Funds investment objective is not a fundamental policy and may be changed by the Funds Board of Trustees without shareholder approval.
C000232435 Performance
Total returns for C000232435 (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | -1.0% |
C000232435 Risk Information
Risk metrics for C000232435, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 22.1%
C000232435 Costs and Fees
C000232435 costs about $65 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.65%
- Gross expense ratio: 0.65%
- Portfolio turnover: 85%
- Brokerage commissions: 9.34 bps of average net assets (SEC N-CEN)
C000232435 Cashflows
Over the 12 months to 2023-04, Direxion mRNA ETF had net inflows of $7.36M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2023-04 | $2.97M |
| 2023-03 | $339.07K |
| 2023-02 | $1.14M |
| 2023-01 | $386.29K |
| 2022-12 | $1.84M |
| 2022-11 | $357.20K |
C000232435 Debt Constituents
No individual debt constituents are reported in Direxion mRNA ETF's latest SEC N-PORT filing.
C000232435 Prospectus and SEC Filings
Official Direxion mRNA ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2022-02-28
- Prospectus (485BPOS) — filed 2021-12-02
- Prospectus supplement (497) — filed 2023-03-02
- Portfolio holdings (N-PORT) — filed 2023-06-29
- Portfolio holdings (N-PORT) — filed 2023-03-31
- Portfolio holdings (N-PORT) — filed 2022-12-27
- Annual census (N-CEN) — filed 2023-01-17
Related Funds
Other Europe Blend / Core Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.